FGFR2 and intrahepatic cholangiocarcinoma: This aligns with the FIGHT-202 trial which was a pivotal phase II study of pemigatinib in locally advanced/metastatic ICC which reported a 35.5% objective response rate (ORR) in unresectable FGFR2-aberrant cases (12).